Mantle cell lymphoma
ICD-10 C83.1 · ICD-11 2A85.5

Management of Asymptomatic Mantle Cell Lymphoma with Low-Risk Features (Leukemic, SOX11-Negative, Low Ki-67)

Not all mantle cell lymphoma requires immediate treatment. A distinct subset presents asymptomatically with features that indicate a more indolent course — guiding a carefully structured approach that differs substantially from standard MCL protocols.

Clinical Scenario

This protocol applies to patients with asymptomatic mantle cell lymphoma demonstrating the following low-risk profile:

This constellation of features characterises an indolent form of MCL. The presentation can also include a MALT-like pattern of mostly extranodal disease with low Ki-67 and classical morphology.

Approach

The cornerstone of management in this setting is active observation rather than immediate treatment initiation, with structured follow-up at defined intervals. The full protocol specifies monitoring frequency, the investigations required at each visit, and the precise conditions under which intervention — including the limited contexts in which targeted approaches may be considered — would be triggered…

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1002/hem3.70233

Although definitions vary in the literature, "indolent" MCL is often characterized by a leukemic presentation, SOX11 negativity, and low proliferation index (Ki‐67), although an indolent "MALT‐like" form of mostly extranodal disease, again with low Ki67% and classical morphology, is also recognized.

Asymptomatic MCL patients with low‐risk features managed by a watch‐and‐wait strategy should be monitored initially every 3 months, and then every 3–6 months by physical examination, imaging (as clinically required), blood counts, and biochemistry [V, B].

Early intervention with targeted therapy should be performed only in the context of prospective clinical trials [II, C].

At clinical progression, treatment will be initiated as for other MCL as below [V, B].

View source ↗